IMUNON, Inc. and The Wistar Institute announced the signing of a first collaborative research agreement to research and develop new vaccine formulations utilizing IMUNON's PLACCINE modality for the development of vaccines for infectious diseases. IMUNON's platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.3 USD | -2.26% | +14.04% | +91.18% |
Apr. 18 | Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine | MT |
Apr. 18 | Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+91.18% | 12.22M | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.31% | 22.2B | |
-16.53% | 21.23B | |
-8.72% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- IMNN Stock
- News Imunon, Inc.
- Imunon, Inc. Enters into Collaborative Research Agreement with the Wistar Institute’S Vaccine & Immunotherapy Center